甲狀腺功能測試市場- 按產品（儀器、試劑和試劑盒）、測試類型（TSH 測試、T4 測試、T3 測試、免費T4 測試）、最終用途（醫院和診所、診斷實驗室、研究和學術機構） - 全球預測（2024 - 2032）

甲狀腺功能測試市場規模預計從 2024 年到 2032 年將以 6.1% 的複合年成長率擴大。根據美國癌症協會的資料，預計 2024 年美國將新增 44,020 例甲狀腺癌病例。

診斷方法的重大進步進一步提高了準確性和效率，使測試變得更加容易和可靠。醫療保健基礎設施的擴張，特別是在新興經濟體，正在改善診斷服務的取得。日益成長的老齡化人口更容易出現甲狀腺問題，進一步加速了檢測需求。多項政府措施和健康計畫正在鼓勵甲狀腺疾病的早期發現、診斷和管理。預防性醫療實踐的日益普及也對產業成長產生了積極影響。

市場分為產品、測試類型、最終用途和地區。

根據產品，在提高測試準確性和效率的診斷技術進步的帶動下，儀器領域的甲狀腺功能測試產業價值預計將在 2024 年至 2032 年間大幅成長。醫療保健提供者對早期診斷和監測的日益關注正在推動先進儀器的採用。對醫療保健基礎設施的投資不斷增加以及診斷實驗室的擴張，特別是在新興市場，將增加產品需求。

就最終用途而言，預計到 2032 年，診斷實驗室領域的甲狀腺功能檢測市場將以顯著速度成長。實驗室設備的重大進步正在提高測試效率和精度。醫療保健基礎設施投資的增加以及新興市場診斷服務的擴張也將有利於該領域的成長。

從地區來看，由於人們對甲狀腺疾病的認知不斷提高以及醫療保健支出不斷增加，預計亞太地區甲狀腺功能檢測市場規模將在 2024 年至 2032 年間大幅成長。甲狀腺疾病的流行，加上診斷基礎設施的改進，正在加速這些測試的部署。政府健康計劃和促進甲狀腺疾病早期診斷和管理的計劃的啟動將進一步推動區域產業的發展。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 甲狀腺疾病的發生率增加
    • 診斷技術的進步
    • 增加醫療保健支出
    • 篩檢項目數量不斷增加
  • 產業陷阱與挑戰
    • 嚴格的監管場景
    • 診斷測試成本高
• 成長潛力分析
• 技術景觀
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 儀器
• 試劑及試劑盒
• 其他產品

第 6 章：市場估計與預測：按測試類型，2021 - 2032 年

• 主要趨勢
• TSH（促甲狀腺激素）測試
• T4（甲狀腺素）測試
• T3（碘甲狀腺原氨酸）測試
• 免費T4測試
• 免費T3測試
• 其他測試類型

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 醫院和診所
• 診斷實驗室
• 研究與學術機構
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Abbott Laboratories
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Cipla Limited
• Danaher Corporation
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Quidelortho Corporation
• Randox Laboratories Ltd.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

Thyroid Function Testing Market size is projected to expand at 6.1% CAGR from 2024 to 2032. The growing prevalence of thyroid disorders like hypothyroidism and hyperthyroidism is necessitating regular monitoring and diagnosis. According to data from the American Cancer Society, the U.S. is projected to witness 44,020 new cases of thyroid cancer in 2024. The rising awareness about thyroid health and its impacts on overall well-being is also boosting the demand for testing techniques.

Significant advancements in diagnostic methods are further enhancing accuracy and efficiency, making tests more accessible and reliable. The expansion of healthcare infrastructure, particularly in emerging economies, is improving access to diagnostic services. The growing aging population is more susceptible to thyroid issues, further accelerating the testing demand. Multiple government initiatives and health programs are encouraging the early detection, diagnosis, and management of thyroid conditions. The increasing adoption of preventive healthcare practices is also positively influencing the industry growth.

The market is bifurcated into product, test type, end-use, and region.

Based on product, the thyroid function testing industry value from the instruments segment is estimated to rise at significant rate between 2024 and 2032, led by advancements in diagnostic technology for enhancing test accuracy and efficiency. The growing focus of healthcare providers on early diagnosis and monitoring is fueling the adoption of advanced instruments. The rising investments in healthcare infrastructure and the expansion of diagnostic laboratories, particularly in emerging markets will add to the product demand.

With respect to end-use, the thyroid function testing market from the diagnostic laboratories segment is estimated to grow at significant rate through 2032. This is due to the growing burden of thyroid disorders and the high demand for accurate, reliable testing. Significant advancements in laboratory equipment are improving testing efficiency and precision. The rising investments in healthcare infrastructure and the expansion of diagnostic services in emerging markets will also favor the segment growth.

Regionally, the Asia Pacific thyroid function testing market size is projected to witness substantial gains between 2024 and 2032, owing to the rising awareness of thyroid disorders and increasing healthcare expenditure. The prevalence of thyroid diseases, coupled with improved diagnostic infrastructure is accelerating the deployment of these tests. The launch of government health initiatives and programs for promoting the early diagnosis and management of thyroid conditions will further fuel the regional industry progression.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of thyroid disorders
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Increasing healthcare expenditure
    • 3.2.1.4 Rising number of screening programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High cost of diagnostic tests
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Reagent & kits
• 5.4 Other products

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 TSH (thyroid stimulating hormone) test
• 6.3 T4 (thyroxine) test
• 6.4 T3 (riiodothyronine) test
• 6.5 Free T4 test
• 6.6 Free T3 test
• 6.7 Other test types

Chapter 7 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals & clinics
• 7.3 Diagnostic laboratories
• 7.4 Research & academic institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 bioMerieux S.A.
• 9.3 Bio-Rad Laboratories, Inc.
• 9.4 Cipla Limited
• 9.5 Danaher Corporation
• 9.6 DiaSorin S.p.A.
• 9.7 F. Hoffmann-La Roche Ltd.
• 9.8 Quidelortho Corporation
• 9.9 Randox Laboratories Ltd.
• 9.10 Siemens Healthineers AG
• 9.11 Thermo Fisher Scientific Inc.